Hovi L, Rajantie J, Perkkiö M, Sainio K, Sipilä I, Siimes M A
Children's Hospital, University of Helsinki, Finland.
Bone Marrow Transplant. 1990 Mar;5(3):183-6.
Eleven patients between the ages of 6 and 18 years who had been treated for acute leukemia were investigated for growth and growth hormone (GH) secretion. All had undergone bone marrow transplantation (BMT) between 0.7 and 5.1 (median 2.0) years previously. Preparation of patients for BMT had included high-dose cyclophosphamide and total body irradiation. In the eight patients at risk of growth failure, the relative height decreased 0.5-2.5 SD units (median 1.0) during the follow-up period. Eight patients secreted subnormal amounts of GH as studied by measuring spontaneous pulsatile GH secretion overnight. The maximal nocturnal GH peak varied between 3.3 and 28.3 micrograms/l (median 9.3). The mean nocturnal GH concentration varied from 1.2 to 8.3 micrograms/l (median 2.3) and depended on the length of the follow-up period. We conclude that deficient GH secretion is one reason for poor growth after BMT. A good growth response to GH substitution would support the role of GH deficiency in the observed growth retardation after BMT.
对11名曾接受急性白血病治疗的6至18岁患者进行了生长及生长激素(GH)分泌情况的调查。所有患者均在0.7至5.1(中位数2.0)年前接受了骨髓移植(BMT)。患者接受BMT的预处理包括大剂量环磷酰胺和全身照射。在8名有生长发育迟缓风险的患者中,随访期间相对身高下降了0.5至2.5个标准差单位(中位数1.0)。通过夜间测量自发性脉冲式GH分泌研究发现,8名患者分泌的GH量低于正常水平。夜间最大GH峰值在3.3至28.3微克/升之间(中位数9.3)。夜间GH平均浓度在1.2至8.3微克/升之间(中位数2.3),且取决于随访期的长短。我们得出结论,GH分泌不足是BMT后生长发育不良的一个原因。对GH替代治疗有良好的生长反应将支持GH缺乏在BMT后观察到的生长迟缓中所起的作用。